1
|
Grattoni A, Cooke JP. Emerging nanotechnologies in cardiovascular medicine. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2021; 39:102472. [PMID: 34715052 DOI: 10.1016/j.nano.2021.102472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/10/2021] [Revised: 09/15/2021] [Accepted: 09/30/2021] [Indexed: 11/19/2022]
Affiliation(s)
- Alessandro Grattoni
- Department of Nanomedicine, Houston Methodist Research Institute; Department of Surgery, Houston Methodist Hospital; Department of Radiation Oncology, Houston Methodist Hospital.
| | - John P Cooke
- Department of Cardiovascular Sciences, Center for Cardiovascular Regeneration, Houston Methodist Research Institute; Center for RNA Therapeutics, Houston Methodist Hospital, Houston, TX, USA
| |
Collapse
|
2
|
A H, Yang Z, Hu R, Chen YF. Roles of energy dissipation and asymmetric wettability in spontaneous imbibition dynamics in a nanochannel. J Colloid Interface Sci 2021; 607:1023-1035. [PMID: 34571292 DOI: 10.1016/j.jcis.2021.09.051] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2021] [Revised: 08/29/2021] [Accepted: 09/09/2021] [Indexed: 01/28/2023]
Abstract
HYPOTHESIS The imbibition dynamics is controlled by energy dissipation mechanisms and influenced by asymmetric wettability in a nanochannel. We hypothesize that the imbibition dynamics can be described by a combined model of the Lucas-Washburn equation and the Cox-Voinov law considering velocity-dependent contact angles. METHODS Molecular dynamics simulations are utilized to investigate the imbibition dynamics. A wide range of wetting conditions is achieved via adjusting the liquid-solid interaction parameters, and the spontaneous imbibition processes are quantified and compared. FINDINGS The critical condition for the occurrence of spontaneous imbibition is analyzed from a surface energy perspective. The analyses of energy conversion and dissipation indicate that the viscous dissipation is dominant during spontaneous imbibition. The classical Lucas-Washburn equation is modified with the Cox-Voinov law considering the effect of the dynamic contact angle and an effective equilibrium contact angle. We show that the proposed theory well captures the imbibition dynamics embodied in the growth of imbibition length as well as the transient interface shape and velocity for both the symmetric and asymmetric wetting conditions. In nanochannels with asymmetric wettability, the imbibition length difference between the sidewalls and interface oscillations increases with wetting disparity. Our findings deepen the understanding of imbibition dynamics on the nanoscale, and provide a theoretical reference for relevant applications.
Collapse
Affiliation(s)
- Hubao A
- State Key Laboratory of Water Resources and Hydropower Engineering Science, Wuhan University, Wuhan 430072, China; Key Laboratory of Rock Mechanics in Hydraulic Structural Engineering of the Ministry of Education, Wuhan University, Wuhan 430072, China
| | - Zhibing Yang
- State Key Laboratory of Water Resources and Hydropower Engineering Science, Wuhan University, Wuhan 430072, China; Key Laboratory of Rock Mechanics in Hydraulic Structural Engineering of the Ministry of Education, Wuhan University, Wuhan 430072, China.
| | - Ran Hu
- State Key Laboratory of Water Resources and Hydropower Engineering Science, Wuhan University, Wuhan 430072, China; Key Laboratory of Rock Mechanics in Hydraulic Structural Engineering of the Ministry of Education, Wuhan University, Wuhan 430072, China
| | - Yi-Feng Chen
- State Key Laboratory of Water Resources and Hydropower Engineering Science, Wuhan University, Wuhan 430072, China; Key Laboratory of Rock Mechanics in Hydraulic Structural Engineering of the Ministry of Education, Wuhan University, Wuhan 430072, China
| |
Collapse
|
3
|
Nanotechnology applications for cardiovascular disease treatment: Current and future perspectives. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2021; 34:102387. [PMID: 33753283 DOI: 10.1016/j.nano.2021.102387] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/29/2020] [Revised: 02/24/2021] [Accepted: 03/03/2021] [Indexed: 11/22/2022]
Abstract
A large majority of cardiovascular nanomedicine research has focused on fabricating designer nanoparticles for improved targeting as a means to overcome biological barriers. For cardiac related disorders, such as atherosclerosis, hypertension, and myocardial infarction, designer micro or nanoparticles are often administered into the vasculature or targeted vessel with the hope to circumvent problems associated with conventional drug delivery, including negative systemic side effects. Additionally, novel nano-drug carriers that enter circulation can be selectively uptaken by immune cells with the intended purpose that they modulate inflammatory processes and migrate locally to plaque for therapeutic payload delivery. Indeed, innovative design in nanoparticle composition, formulation, and functionalization has advanced the field as a means to achieve therapeutic efficacy for a variety of cardiac disease indications. This perspective aims to discuss these advances and provide new interpretations of how nanotechnology can be best applied to aid in cardiovascular disease treatment. In an effort to spark discussions on where the field of research should go, we share our outlook in new areas of nanotechnological inclusion and integration, such as in vascular, implantable, or wearable device technologies as well as nanocomposites and nanocoatings. Further, as cardiovascular diseases (CVD) increasingly claim a number of lives globally, we propose more attention should be placed by researchers on nanotechnological approaches for risk factor treatment to aid in early prevention and treatment of CVD.
Collapse
|
4
|
Resveratrol Nanoparticles: A Promising Therapeutic Advancement over Native Resveratrol. Processes (Basel) 2020. [DOI: 10.3390/pr8040458] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
The importance of fruit-derived resveratrol (RES) in the treatment of various diseases has been discussed in various research publications. Those research findings have indicated the ability of the molecule as therapeutic in the context of in vitro and in vivo conditions. Mostly, the application of RES in in vivo conditions, encapsulation processes have been carried out using various nanoparticles that are made of biocompatible biomaterials, which are easily digested or metabolized, and RES is absorbed effectively. These biomaterials are non-toxic and are safe to be used as components in the biotherapeutics. They are made from naturally available by-products of food materials like zein or corn or components of the physiological system as with lipids. The versatility of the RES nanoparticles in their different materials, working range sizes, specificity in their targeting in various human diseases, and the mechanisms associated with them are discussed in this review.
Collapse
|
5
|
Filgueira CS, Igo SR, Wang DK, Hirsch M, Schulz DG, Bruckner BA, Grattoni A. Technologies for intrapericardial delivery of therapeutics and cells. Adv Drug Deliv Rev 2019; 151-152:222-232. [PMID: 30797957 DOI: 10.1016/j.addr.2019.02.006] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2019] [Revised: 02/13/2019] [Accepted: 02/15/2019] [Indexed: 12/12/2022]
Abstract
The pericardium, which surrounds the heart, provides a unique enclosed volume and a site for the delivery of agents to the heart and coronary arteries. While strategies for targeting the delivery of therapeutics to the heart are lacking, various technologies and nanodelivery approaches are emerging as promising methods for site specific delivery to increase therapeutic myocardial retention, efficacy, and bioactivity, while decreasing undesired systemic effects. Here, we provide a literature review of various approaches for intrapericardial delivery of agents. Emphasis is given to sustained delivery approaches (pumps and catheters) and localized release (patches, drug eluting stents, and support devices and meshes). Further, minimally invasive access techniques, pericardial access devices, pericardial washout and fluid analysis, as well as therapeutic and cell delivery vehicles are presented. Finally, several promising new therapeutic targets to treat heart diseases are highlighted.
Collapse
|
6
|
Pons-Faudoa FP, Ballerini A, Sakamoto J, Grattoni A. Advanced implantable drug delivery technologies: transforming the clinical landscape of therapeutics for chronic diseases. Biomed Microdevices 2019; 21:47. [PMID: 31104136 PMCID: PMC7161312 DOI: 10.1007/s10544-019-0389-6] [Citation(s) in RCA: 100] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Chronic diseases account for the majority of all deaths worldwide, and their prevalence is expected to escalate in the next 10 years. Because chronic disorders require long-term therapy, the healthcare system must address the needs of an increasing number of patients. The use of new drug administration routes, specifically implantable drug delivery devices, has the potential to reduce treatment-monitoring clinical visits and follow-ups with healthcare providers. Also, implantable drug delivery devices can be designed to maintain drug concentrations in the therapeutic window to achieve controlled, continuous release of therapeutics over extended periods, eliminating the risk of patient non-compliance to oral treatment. A higher local drug concentration can be achieved if the device is implanted in the affected tissue, reducing systemic adverse side effects and decreasing the challenges and discomfort of parenteral treatment. Although implantable drug delivery devices have existed for some time, interest in their therapeutic potential is growing, with a global market expected to reach over $12 billion USD by 2018. This review discusses implantable drug delivery technologies in an advanced stage of development or in clinical use and focuses on the state-of-the-art of reservoir-based implants including pumps, electromechanical systems, and polymers, sites of implantation and side effects, and deployment in developing countries.
Collapse
Affiliation(s)
- Fernanda P Pons-Faudoa
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX, 77030, USA
- School of Medicine and Health Sciences, Tecnologico de Monterrey, Avenida Eugenio Garza Sada 2501, 64849, Monterrey, NL, Mexico
| | - Andrea Ballerini
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX, 77030, USA
- Department of Oncology and Onco-Hematology, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy
| | - Jason Sakamoto
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX, 77030, USA
| | - Alessandro Grattoni
- Department of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX, 77030, USA.
- Department of Surgery, Houston Methodist Hospital, 6550 Fannin Street, Houston, TX, 77030, USA.
- Department of Radiation Oncology, Houston Methodist Hospital, 6550 Fannin Street, Houston, TX, 77030, USA.
| |
Collapse
|
7
|
Farina M, Alexander JF, Thekkedath U, Ferrari M, Grattoni A. Cell encapsulation: Overcoming barriers in cell transplantation in diabetes and beyond. Adv Drug Deliv Rev 2019; 139:92-115. [PMID: 29719210 DOI: 10.1016/j.addr.2018.04.018] [Citation(s) in RCA: 112] [Impact Index Per Article: 22.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2018] [Revised: 03/19/2018] [Accepted: 04/25/2018] [Indexed: 02/07/2023]
Abstract
Cell-based therapy is emerging as a promising strategy for treating a wide range of human diseases, such as diabetes, blood disorders, acute liver failure, spinal cord injury, and several types of cancer. Pancreatic islets, blood cells, hepatocytes, and stem cells are among the many cell types currently used for this strategy. The encapsulation of these "therapeutic" cells is under intense investigation to not only prevent immune rejection but also provide a controlled and supportive environment so they can function effectively. Some of the advanced encapsulation systems provide active agents to the cells and enable a complete retrieval of the graft in the case of an adverse body reaction. Here, we review various encapsulation strategies developed in academic and industrial settings, including the state-of-the-art technologies in advanced preclinical phases as well as those undergoing clinical trials, and assess their advantages and challenges. We also emphasize the importance of stimulus-responsive encapsulated cell systems that provide a "smart and live" therapeutic delivery to overcome barriers in cell transplantation as well as their use in patients.
Collapse
|
8
|
Di Trani N, Jain P, Chua CYX, Ho JS, Bruno G, Susnjar A, Pons-Faudoa FP, Sizovs A, Hood RL, Smith ZW, Ballerini A, Filgueira CS, Grattoni A. Nanofluidic microsystem for sustained intraocular delivery of therapeutics. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2018; 16:1-9. [PMID: 30468870 DOI: 10.1016/j.nano.2018.11.002] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/29/2018] [Revised: 10/03/2018] [Accepted: 11/06/2018] [Indexed: 02/07/2023]
Abstract
Globally, 145.2 million people suffer from moderate to severe vision impairment or blindness due to preventable or treatable causes. However, patient adherence to topical or intravitreal treatment is a leading cause of poor outcomes. To address this issue, we designed an intraocularly implantable device called the nanofluidic Vitreal System for Therapeutic Administration (nViSTA) for continuous and controlled drug release based on a nanochannel membrane that obviates the need for pumps or actuation. In vitro release analysis demonstrated that our device achieves sustained release of bimatoprost (BIM) and dexamethasone (DEX) at concentrations within clinically relevant therapeutic window. In this proof of concept study, we constructed an anatomically similar in silico human eye model to simulate DEX release from our implant and gain insight into intraocular pharmacokinetics profile. Overall, our drug-agnostic intraocular implant represents a potentially viable platform for long-term treatment of various chronic ophthalmologic diseases, including diabetic macular edema and uveitis.
Collapse
Affiliation(s)
- Nicola Di Trani
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA; University of Chinese Academy of Science (UCAS), Shijingshan, Beijing, China
| | - Priya Jain
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
| | | | - Jeremy S Ho
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA; Weill Cornell Medical College, Weill Cornell Medicine, New York, NY, USA
| | - Giacomo Bruno
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
| | - Antonia Susnjar
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
| | - Fernanda Paola Pons-Faudoa
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA; Tecnologico de Monterrey, School of Medicine and Health Sciences, Monterrey, NL, Mexico
| | - Antons Sizovs
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
| | - R Lyle Hood
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
| | - Zachary W Smith
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
| | - Andrea Ballerini
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA; Department of Oncology and Onco-Hematology, University of Milan, Milan, Italy
| | - Carly S Filgueira
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA; Department of Cardiovascular Surgery, Houston Methodist Hospital, Houston, TX, USA
| | - Alessandro Grattoni
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA; Department of Surgery, Houston Methodist Hospital, Houston, TX, USA; Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX, USA.
| |
Collapse
|
9
|
Scorrano G, Bruno G, Trani ND, Ferrari M, Pimpinelli A, Grattoni A. Gas Flow at the Ultra-nanoscale: Universal Predictive Model and Validation in Nanochannels of Ångstrom-Level Resolution. ACS APPLIED MATERIALS & INTERFACES 2018; 10:32233-32238. [PMID: 30185043 PMCID: PMC6836450 DOI: 10.1021/acsami.8b11455] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/19/2023]
Abstract
Gas transport across nanoscale pores is determinant in molecular exchange in living organisms as well as in a broad spectrum of technologies. Here, we report an unprecedented theoretical and experimental analysis of gas transport in a consistent set of confining nanochannels ranging in size from the ultra-nanoscale to the sub-microscale. A generally applicable theoretical approach quantitatively predicting confined gas flow in the Knudsen and transition regime was developed. Unlike current theories, specifically designed for very simple channel geometries, our approach can be applied to virtually all geometries, for which the probability distribution of path lengths for particle-interface collisions can be computed, either analytically or by numerical simulations. To generate a much needed benchmark experimental model, we manufactured extremely reproducible membranes with two-dimensional nanochannels. Channel sizes ranged from 2.5 to 250 nm, and angstrom level of size control and interface tolerances were achieved using leading-edge nanofabrication techniques. We then measured gas flow in the Knudsen number range from 0.2 to 20. Excellent agreement between theoretical predictions and experimental data was found, demonstrating the validity and potential of our approach.
Collapse
Affiliation(s)
- Giovanni Scorrano
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas,77030, USA
- Department of Material Science and Nanoengineering, Rice University, Houston, Texas, 77005, USA
| | - Giacomo Bruno
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas,77030, USA
| | - Nicola Di Trani
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas,77030, USA
| | - Mauro Ferrari
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas,77030, USA
| | - Alberto Pimpinelli
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas,77030, USA
- Smalley-Curl Institute, Rice University, Houston, Texas, 77005, USA
| | - Alessandro Grattoni
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas,77030, USA
- Department of Surgery, Houston Methodist Hospital, Houston, Texas, 77030, USA
- Department of Radiation Oncology, Houston Methodist Hospital, Houston, Texas, 77030, USA
- corresponding author:
| |
Collapse
|
10
|
Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer. J Control Release 2018; 285:23-34. [DOI: 10.1016/j.jconrel.2018.06.035] [Citation(s) in RCA: 39] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2018] [Revised: 06/15/2018] [Accepted: 06/28/2018] [Indexed: 12/11/2022]
|
11
|
Efficacy of sustained delivery of GC-1 from a Nanofluidic system in a spontaneously obese non-human primate: a case study. Biomed Microdevices 2018; 20:49. [DOI: 10.1007/s10544-018-0296-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
12
|
Habbu P, Hiremath M, Madagundi S, Vankudri R, Patil B, Savant C. Phytotherapeutics of polyphenolic-loaded drug delivery systems: A review. Pharmacogn Rev 2018. [DOI: 10.4103/phrev.phrev_33_17] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
13
|
Hood RL, Hood GD, Ferrari M, Grattoni A. Pioneering medical advances through nanofluidic implantable technologies. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY 2017; 9. [DOI: 10.1002/wnan.1455] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/08/2016] [Revised: 11/27/2016] [Accepted: 12/17/2016] [Indexed: 12/11/2022]
Affiliation(s)
- R. Lyle Hood
- Department of Nanomedicine; Houston Methodist Research Institute; Houston TX USA
- Department of Mechanical Engineering; University of Texas San Antonio; San Antonio TX USA
| | - Gold Darr Hood
- Department of Nanomedicine; Houston Methodist Research Institute; Houston TX USA
| | - Mauro Ferrari
- Department of Nanomedicine; Houston Methodist Research Institute; Houston TX USA
| | - Alessandro Grattoni
- Department of Nanomedicine; Houston Methodist Research Institute; Houston TX USA
| |
Collapse
|
14
|
Filgueira CS, Ballerini A, Nicolov E, Chua CYX, Jain P, Smith ZW, Gilbert AL, Scaglione F, Grattoni A. A pharmacokinetic study of GC-1 delivery using a nanochannel membrane device. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2017; 13:1739-1744. [PMID: 28259802 DOI: 10.1016/j.nano.2017.02.012] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Revised: 01/20/2017] [Accepted: 02/14/2017] [Indexed: 12/25/2022]
Abstract
This study demonstrated a nanochannel membrane device (NMD) for controlled and sustained release of GC-1 in rats, in the context of the treatment of metabolic syndrome. Release profiles were established in vitro both with and without 5% labrasol for over 2 months. In vivo pharmacokinetic evaluation showed effective GC-1 plasma concentrations, which resulted in significant reductions in body weight after just one week of treatment when compared to the NMD releasing vehicle only (PBS). We also provided evidence that rats treated with NMD-GC-1 present sub-active thyroids and clear differences in the morphology of the epithelium and follicles as compared to the controls, while the heart showed changes in weight. Moreover, body temperatures remained stable throughout treatment, and glucose, pancreatic islet size, and liver histology appeared similar between the treated and control groups. Prolonged constant administration of GC-1 from the NMD proved to be a valid strategy to facilitate weight loss.
Collapse
Affiliation(s)
- Carly S Filgueira
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
| | - Andrea Ballerini
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA; Department of Oncology and Onco-Hematology, University of Milan, Milan, Italy
| | - Eugenia Nicolov
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
| | | | - Priya Jain
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
| | - Zachary W Smith
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
| | - April L Gilbert
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA
| | - Francesco Scaglione
- Department of Oncology and Onco-Hematology, University of Milan, Milan, Italy
| | - Alessandro Grattoni
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA.
| |
Collapse
|
15
|
Sabek OM, Farina M, Fraga DW, Afshar S, Ballerini A, Filgueira CS, Thekkedath UR, Grattoni A, Gaber AO. Three-dimensional printed polymeric system to encapsulate human mesenchymal stem cells differentiated into islet-like insulin-producing aggregates for diabetes treatment. J Tissue Eng 2016; 7:2041731416638198. [PMID: 27152147 PMCID: PMC4843232 DOI: 10.1177/2041731416638198] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2015] [Accepted: 02/18/2016] [Indexed: 01/19/2023] Open
Abstract
Diabetes is one of the most prevalent, costly, and debilitating diseases in the world. Pancreas and islet transplants have shown success in re-establishing glucose control and reversing diabetic complications. However, both are limited by donor availability, need for continuous immunosuppression, loss of transplanted tissue due to dispersion, and lack of vascularization. To overcome the limitations of poor islet availability, here, we investigate the potential of bone marrow–derived mesenchymal stem cells differentiated into islet-like insulin-producing aggregates. Islet-like insulin-producing aggregates, characterized by gene expression, are shown to be similar to pancreatic islets and display positive immunostaining for insulin and glucagon. To address the limits of current encapsulation systems, we developed a novel three-dimensional printed, scalable, and potentially refillable polymeric construct (nanogland) to support islet-like insulin-producing aggregates’ survival and function in the host body. In vitro studies showed that encapsulated islet-like insulin-producing aggregates maintained viability and function, producing steady levels of insulin for at least 4 weeks. Nanogland—islet-like insulin-producing aggregate technology here investigated as a proof of concept holds potential as an effective and innovative approach for diabetes cell therapy.
Collapse
Affiliation(s)
- Omaima M Sabek
- Department of Surgery, Houston Methodist Hospital, Houston, TX, USA
| | - Marco Farina
- Department of Nanomedicine, Institute for Academic Medicine, Houston Methodist Research Institute, Houston, TX, USA; Department of Electronics and Telecommunications, Politecnico di Torino, Torino, Italy
| | - Daniel W Fraga
- Department of Surgery, Houston Methodist Hospital, Houston, TX, USA
| | - Solmaz Afshar
- Department of Surgery, Houston Methodist Hospital, Houston, TX, USA
| | - Andrea Ballerini
- Department of Nanomedicine, Institute for Academic Medicine, Houston Methodist Research Institute, Houston, TX, USA; Department of Biotechnology and Translational Medicine, The University of Milan, Milan, Italy
| | - Carly S Filgueira
- Department of Nanomedicine, Institute for Academic Medicine, Houston Methodist Research Institute, Houston, TX, USA
| | - Usha R Thekkedath
- Department of Nanomedicine, Institute for Academic Medicine, Houston Methodist Research Institute, Houston, TX, USA
| | - Alessandro Grattoni
- Department of Nanomedicine, Institute for Academic Medicine, Houston Methodist Research Institute, Houston, TX, USA
| | - A Osama Gaber
- Department of Surgery, Houston Methodist Hospital, Houston, TX, USA
| |
Collapse
|
16
|
Yang Z, Cai Q, Chen N, Zhou X, Hong J. Selective separation and identification of metabolite groups of Polygonum cuspidatum extract in rat plasma using dispersion solid-phase extraction by magnetic molecularly imprinted polymers coupled with LC/Q-TOF-MS. RSC Adv 2016. [DOI: 10.1039/c5ra26695e] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
In this work, magnetic molecularly imprinted polymers (MMIPs) were successfully prepared for specific recognition and selective enrichment of metabolite groups of Polygonum cuspidatum extract in rat plasma.
Collapse
Affiliation(s)
- Zaiyue Yang
- School of Pharmacy
- Nanjing Medical University
- Nanjing 210029
- PR China
| | - Qizhi Cai
- School of Pharmacy
- Nanjing Medical University
- Nanjing 210029
- PR China
| | - Ning Chen
- School of Pharmacy
- Nanjing Medical University
- Nanjing 210029
- PR China
- Jiangsu Province Institute of Materia Media
| | - Xuemin Zhou
- School of Pharmacy
- Nanjing Medical University
- Nanjing 210029
- PR China
| | - Junli Hong
- School of Pharmacy
- Nanjing Medical University
- Nanjing 210029
- PR China
| |
Collapse
|
17
|
Impedance characterization, degradation, and in vitro biocompatibility for platinum electrodes on BioMEMS. Biomed Microdevices 2015; 17:24. [PMID: 25663443 DOI: 10.1007/s10544-014-9909-6] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Fine control of molecular transport through microfluidic systems can be obtained by modulation of an applied electrical field across channels with the use of electrodes. In BioMEMS designed for biological fluids and in vivo applications, electrodes must be biocompatible, biorobust and stable. In this work, the analysis and characterization of platinum (Pt) electrodes integrated on silicon substrates for biomedical applications are presented. Electrodes were incorporated on the surface of silicon chips by adhesion of laminated Pt foils or deposited at 30°, 45° or 90° angle by e-beam or physical vapor (sputtering) methods. Electrical and physical properties of the electrodes were quantified and evaluated using electrical impedance spectroscopy and modelling of the electrode-electrolyte interfaces. Electrode degradation in saline solution at pH 7.4 was tested at room temperature and under accelerated conditions (90 °C), both in the presence and absence of an applied electrical potential. Degradation was quantified using atomic force microscopy (AFM) and inductively coupled plasma mass spectroscopy (ICP-MS). Biocompatibility was assessed by MTT proliferation assay with human dermal fibroblasts. Results demonstrated that the deposited electrodes were biocompatible with negligible material degradation and exhibited electrochemical behavior similar to Pt foils, especially for e-beam deposited electrodes. Finally, Pt electrodes e-beam deposited on silicon nanofabricated nanochannel membranes were evaluated for controlled drug delivery applications. By tuning a low applied electrical potential (<1.5 VDC) to the electrodes, temporal modulation of the dendritic fullerene 1 (DF-1) release from a source reservoir was successfully achieved as a proof of concept, highlighting the potential of deposited electrodes in biomedical applications.
Collapse
|
18
|
Geninatti T, Hood RL, Bruno G, Jain P, Nicolov E, Ziemys A, Grattoni A. Sustained Administration of Hormones Exploiting Nanoconfined Diffusion through Nanochannel Membranes. MATERIALS 2015; 8:5276-5288. [PMID: 27293533 PMCID: PMC4898476 DOI: 10.3390/ma8085241] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Implantable devices may provide a superior means for hormone delivery through maintaining serum levels within target therapeutic windows. Zero-order administration has been shown to reach an equilibrium with metabolic clearance, resulting in a constant serum concentration and bioavailability of released hormones. By exploiting surface-to-molecule interaction within nanochannel membranes, it is possible to achieve a long-term, constant diffusive release of agents from implantable reservoirs. In this study, we sought to demonstrate the controlled release of model hormones from a novel nanochannel system. We investigated the delivery of hormones through our nanochannel membrane over a period of 40 days. Levothyroxine, osteocalcin and testosterone were selected as representative hormones based on their different molecular properties and structures. The release mechanisms and transport behaviors of these hormones within 3, 5 and 40 nm channels were characterized. Results further supported the suitability of the nanochannels for sustained administration from implantable platforms.
Collapse
Affiliation(s)
- Thomas Geninatti
- Nanomedicine Department, Houston Methodist Research Institute, Houston, TX 77030, USA; E-Mails: (R.L.H.); (P.J.); (E.N.); (A.Z.)
- College of Materials Science and Engineering, University of Chinese Academy of Sciences, Beijing 100049, China; E-Mail:
| | - R. Lyle Hood
- Nanomedicine Department, Houston Methodist Research Institute, Houston, TX 77030, USA; E-Mails: (R.L.H.); (P.J.); (E.N.); (A.Z.)
| | - Giacomo Bruno
- Nanomedicine Department, Houston Methodist Research Institute, Houston, TX 77030, USA; E-Mails: (R.L.H.); (P.J.); (E.N.); (A.Z.)
- Electronics and Telecommunications Department, Politecnico di Torino, Turin 10024, Italy; E-Mail:
| | - Priya Jain
- Nanomedicine Department, Houston Methodist Research Institute, Houston, TX 77030, USA; E-Mails: (R.L.H.); (P.J.); (E.N.); (A.Z.)
| | - Eugenia Nicolov
- Nanomedicine Department, Houston Methodist Research Institute, Houston, TX 77030, USA; E-Mails: (R.L.H.); (P.J.); (E.N.); (A.Z.)
| | - Arturas Ziemys
- Nanomedicine Department, Houston Methodist Research Institute, Houston, TX 77030, USA; E-Mails: (R.L.H.); (P.J.); (E.N.); (A.Z.)
| | - Alessandro Grattoni
- Nanomedicine Department, Houston Methodist Research Institute, Houston, TX 77030, USA; E-Mails: (R.L.H.); (P.J.); (E.N.); (A.Z.)
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +1-713-441-7324; Fax: +1-713-441-3655
| |
Collapse
|
19
|
Ferrati S, Nicolov E, Zabre E, Geninatti T, Shirkey BA, Hudson L, Hosali S, Crawley M, Khera M, Palapattu G, Grattoni A. The Nanochannel Delivery System for Constant Testosterone Replacement Therapy. J Sex Med 2015; 12:1375-80. [DOI: 10.1111/jsm.12897] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
20
|
Ferrati S, Nicolov E, Bansal S, Zabre E, Geninatti T, Ziemys A, Hudson L, Ferrari M, Goodall R, Khera M, Palapattu G, Grattoni A. Delivering enhanced testosterone replacement therapy through nanochannels. Adv Healthc Mater 2015; 4:446-51. [PMID: 25274059 DOI: 10.1002/adhm.201400348] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2014] [Revised: 07/21/2014] [Indexed: 11/08/2022]
Abstract
Primary or secondary hypogonadism results in a range of signs and symptoms that compromise quality of life and requires life-long testosterone replacement therapy. In this study, an implantable nanochannel system is investigated as an alternative delivery strategy for the long-term sustained and constant release of testosterone. In vitro release tests are performed using a dissolution set up, with testosterone and testosterone:2-hydroxypropyl-β-cyclodextrin (TES:HPCD) 1:1 and 1:2 molar ratio complexes release from the implantable nanochannel system and quantify by HPLC. 1:2 TES:HPCD complex stably achieve 10-15 times higher testosterone solubility with 25-30 times higher in vitro release. Bioactivity of delivered testosterone is verified by LNCaP/LUC cell luminescence. In vivo evaluation of testosterone, luteinizing hormone (LH), and follicle stimulating hormone (FSH) levels by liquid chromatography mass spectrometry (LC/MS) and multiplex assay is performed in castrated Sprague-Dawley rats over 30 d. Animals are treated with the nanochannel implants or degradable testosterone pellets. The 1:2 TES:HPCD nanochannel implant exhibits sustained and clinically relevant in vivo release kinetics and attains physiologically stable plasma levels of testosterone, LH, and FSH. In conclusion, it is demonstrated that by providing long-term steady release 1:2 TES:HPCD nanochannel implants may represent a major breakthrough for the treatment of male hypogonadism.
Collapse
Affiliation(s)
- Silvia Ferrati
- The Department of Nanomedicine; Houston Methodist Research Institute; 6670 Bertner Avenue Houston TX 77030 USA
| | - Eugenia Nicolov
- The Department of Nanomedicine; Houston Methodist Research Institute; 6670 Bertner Avenue Houston TX 77030 USA
| | - Shyam Bansal
- The Department of Nanomedicine; Houston Methodist Research Institute; 6670 Bertner Avenue Houston TX 77030 USA
- Division of Cardiovascular Diseases The University of Alabama at Birmingham; 1530 3 Avenue South Birmingham AL 35294 USA
| | - Erika Zabre
- The Department of Nanomedicine; Houston Methodist Research Institute; 6670 Bertner Avenue Houston TX 77030 USA
| | - Thomas Geninatti
- The Department of Nanomedicine; Houston Methodist Research Institute; 6670 Bertner Avenue Houston TX 77030 USA
| | - Arturas Ziemys
- The Department of Nanomedicine; Houston Methodist Research Institute; 6670 Bertner Avenue Houston TX 77030 USA
| | - Lee Hudson
- NanoMedical Systems Inc.; Austin, TX, 4401 Freidrich Ln 307 Austin TX 78744 USA
| | - Mauro Ferrari
- The Department of Nanomedicine; Houston Methodist Research Institute; 6670 Bertner Avenue Houston TX 77030 USA
| | - Randal Goodall
- NanoMedical Systems Inc.; Austin, TX, 4401 Freidrich Ln 307 Austin TX 78744 USA
| | - Mohit Khera
- Department of Urology; Baylor College of Medicine; 7200 Cambridge Street Houston TX 77030 USA
| | - Ganesh Palapattu
- Department of Urology; University of Michigan; 1500 E Medical Center Drive SPC 5913 Ann Arbor MI 48109 USA
| | - Alessandro Grattoni
- The Department of Nanomedicine; Houston Methodist Research Institute; 6670 Bertner Avenue Houston TX 77030 USA
| |
Collapse
|
21
|
Tunesi M, Prina E, Munarin F, Rodilossi S, Albani D, Petrini P, Giordano C. Cross-linked poly(acrylic acids) microgels and agarose as semi-interpenetrating networks for resveratrol release. JOURNAL OF MATERIALS SCIENCE. MATERIALS IN MEDICINE 2015; 26:5328. [PMID: 25577210 DOI: 10.1007/s10856-014-5328-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/19/2014] [Accepted: 07/20/2014] [Indexed: 06/04/2023]
Abstract
Carbomers, cross-linked poly(acrylic acid) microgels, have been widely used in pharmaceutical formulations as swollen hydrogels. Agarose, whose thermoreversibility may be exploited for drug loading, forms a gel with a mechanism involving coil-helix transition at about 36 °C. In this work carbomer microgels were combined with agarose networks in a semi-interpenetrating polymer network structure, aiming at obtaining suitable delivery systems for the loading and release of molecules with poor bioavailability but high therapeutic interest, like resveratrol. The rheological properties of the formulations and their in vitro cytocompatibility were studied and optimized acting on the neutralizing agent (triethylamine (N,N-diethylethanamine), triethanolamine (tris(2-hydroxyethyl)amine) and sodium hydroxide) and amount of OH donors (1,2-propanediol and glycerol). As a preparation method, autoclaving was introduced to simultaneously obtain heating and sterilising. Among the different neutralizing agents, NaOH was chosen to avoid the use of amines, considering the final application. Without the addition of alcohols as typical OH donors to induce Carbomer gelification, gels with appropriate rheological properties and stability were produced. For this formulation, the release of resveratrol after 7 days was about 80 % of the loaded mass, suggesting it is an interesting approach to be exploited for the development of innovative resveratrol delivery systems.
Collapse
Affiliation(s)
- Marta Tunesi
- Department of Chemistry, Materials and Chemical Engineering "G.Natta" and Unità di Ricerca Consorzio INSTM, Politecnico di Milano, Milan, Italy,
| | | | | | | | | | | | | |
Collapse
|
22
|
New water-soluble carbamate ester derivatives of resveratrol. Molecules 2014; 19:15900-17. [PMID: 25275336 PMCID: PMC6271179 DOI: 10.3390/molecules191015900] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2014] [Revised: 09/22/2014] [Accepted: 09/24/2014] [Indexed: 12/16/2022] Open
Abstract
Low bioavailability severely hinders exploitation of the biomedical potential of resveratrol. Extensive phase-II metabolism and poor water solubility contribute to lowering the concentrations of resveratrol in the bloodstream after oral administration. Prodrugs may provide a solution—protection of the phenolic functions hinders conjugative metabolism and can be exploited to modulate the physicochemical properties of the compound. We report here the synthesis and characterization of carbamate ester derivatives of resveratrol bearing on each nitrogen atom a methyl group and either a methoxy-poly(ethylene glycol)-350 (mPEG-350) or a butyl-glucosyl promoiety conferring high water solubility. Ex vivo absorption studies revealed that the butyl-glucosyl conjugate, unlike the mPEG-350 one, is able to permeate the intestinal wall. In vivo pharmacokinetics confirmed absorption after oral administration and showed that no hydrolysis of the carbamate groups takes place. Thus, sugar groups can be attached to resveratrol to obtain soluble derivatives maintaining to some degree the ability to permeate biomembranes, perhaps by facilitated or active transport.
Collapse
|
23
|
Celia C, Ferrati S, Bansal S, van de Ven AL, Ruozi B, Zabre E, Hosali S, Paolino D, Sarpietro MG, Fine D, Fresta M, Ferrari M, Grattoni A. Sustained zero-order release of intact ultra-stable drug-loaded liposomes from an implantable nanochannel delivery system. Adv Healthc Mater 2014; 3:230-8. [PMID: 23881575 PMCID: PMC3970317 DOI: 10.1002/adhm.201300188] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2013] [Indexed: 11/10/2022]
Abstract
Metronomic chemotherapy supports the idea that long-term, sustained, constant administration of chemotherapeutics, currently not achievable, could be effective against numerous cancers. Particularly appealing are liposomal formulations, used to solubilize hydrophobic therapeutics and minimize side effects, while extending drug circulation time and enabling passive targeting. As liposome alone cannot survive in circulation beyond 48 h, sustaining their constant plasma level for many days is a challenge. To address this, we develop, as a proof of concept, an implantable nanochannel delivery system and ultra-stable PEGylated lapatinib-loaded liposomes, and we demonstrate the release of intact vesicles for over 18 d. Further, we investigate intravasation kinetics of subcutaneously delivered liposomes and verify their biological activity post nanochannel release on BT474 breast cancer cells. The key innovation of this work is the combination of two nanotechnologies to exploit the synergistic effect of liposomes, demonstrated as passive-targeting vectors and nanofluidics to maintain therapeutic constant plasma levels. In principle, this approach could maximize efficacy of metronomic treatments.
Collapse
Affiliation(s)
- Christian Celia
- Department of Nanomedicine, The Methodist Hospital Research Institute, 6670 Bertner Ave. Houston, TX 77030 (USA)
| | - Silvia Ferrati
- Department of Nanomedicine, The Methodist Hospital Research Institute, 6670 Bertner Ave. Houston, TX 77030 (USA)
| | - Shyam Bansal
- Department of Nanomedicine, The Methodist Hospital Research Institute, 6670 Bertner Ave. Houston, TX 77030 (USA)
| | - Anne L. van de Ven
- Department of Nanomedicine, The Methodist Hospital Research Institute, 6670 Bertner Ave. Houston, TX 77030 (USA)
| | - Barbara Ruozi
- Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 183, Modena, 41100 (Italy)
| | - Erika Zabre
- Department of Nanomedicine, The Methodist Hospital Research Institute, 6670 Bertner Ave. Houston, TX 77030 (USA)
| | - Sharath Hosali
- NanoMedical Systems, Inc., 2706 Montopolis Drive Austin, TX 78741, (USA)
| | - Donatella Paolino
- Department of Health Sciences, University “Magna Graecia” of Catanzaro, V.le “S. Venuta” Germaneto – Catanzaro, 88100 (Italy)
| | - Maria Grazia Sarpietro
- Department of Drug Sciences, University of Catania, V.le A. Doria 6, Catania, 95125 (Italy)
| | - Daniel Fine
- Department of Nanomedicine, The Methodist Hospital Research Institute, 6670 Bertner Ave. Houston, TX 77030 (USA)
| | - Massimo Fresta
- Department of Health Sciences, University “Magna Graecia” of Catanzaro, V.le “S. Venuta” Germaneto – Catanzaro, 88100 (Italy)
| | - Mauro Ferrari
- Department of Nanomedicine, The Methodist Hospital Research Institute, 6670 Bertner Ave. Houston, TX 77030 (USA); Department of Medicine, Weill Cornell Medical College, 1300 York Avenue, New York, NY 1006, (USA), Department of Bioengineering, Rice University, 6100 Main Street Houston, TX 77251, (USA), Alliance for NanoHealth, 6670 Bertner Ave., Houston, TX 77030, (USA)
| | | |
Collapse
|